» Articles » PMID: 16493071

Exacerbation of Experimental Autoimmune Encephalomyelitis in P2X7R-/- Mice: Evidence for Loss of Apoptotic Activity in Lymphocytes

Overview
Journal J Immunol
Date 2006 Feb 24
PMID 16493071
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

The purinergic receptor P2X7R is a nucleotide-gated ion channel that has been proposed to function as a major regulator of inflammation. In this study we examined the role of this receptor in regulating inflammation in the CNS by determining the effects of the loss of this receptor (P2X7R-/-) on experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. We show here that P2X7R-/- mice developed more severe clinical and pathological expression of EAE than wild type (WT) controls and that spleen and lymph node cells from P2X7R-/- mice proliferated more vigorously to Ag in vitro. Bone marrow (BM) radiation chimeras revealed that enhanced susceptibility to EAE was detected in chimeric mice of WT host engrafted with P2X7R-/- BM cells, indicating that the genotype of the BM cells regulated disease susceptibility. Coculture of P2X7R-/- macrophages with WT lymphocytes and vice versa showed that enhanced proliferative activity resided within the P2X7R-/- lymphocyte population and correlated with reduced levels of IFN-gamma and NO and apoptosis of lymphocytes. mRNA and protein for IFN-gamma were also significantly reduced in the CNS of P2X7R-/- mice with EAE. FACS analysis of cells isolated from the CNS showed significantly fewer annexin V/propidium iodide-positive lymphocytes in the CNS of P2X7R-/- mice early in the disease, and TUNEL staining of inflamed CNS tissues supported this result. From these data we conclude that enhanced susceptibility of P2X7R-/- mice to EAE reflects a loss of apoptotic activity in lymphocytes, supporting an important role for this receptor in lymphocyte homeostasis.

Citing Articles

Unlocking the therapeutic potential of P2X7 receptor: a comprehensive review of its role in neurodegenerative disorders.

Liu X, Li Y, Huang L, Kuang Y, Wu X, Ma X Front Pharmacol. 2024; 15:1450704.

PMID: 39139642 PMC: 11319138. DOI: 10.3389/fphar.2024.1450704.


Proteomic analysis and functional validation reveal distinct therapeutic capabilities related to priming of mesenchymal stromal/stem cells with IFN-γ and hypoxia: potential implications for their clinical use.

Calligaris M, Zito G, Busa R, Bulati M, Iannolo G, Gallo A Front Cell Dev Biol. 2024; 12:1385712.

PMID: 38882056 PMC: 11179434. DOI: 10.3389/fcell.2024.1385712.


The P2X7 Receptor in Autoimmunity.

Grassi F, Salina G Int J Mol Sci. 2023; 24(18).

PMID: 37762419 PMC: 10531565. DOI: 10.3390/ijms241814116.


Animal Models for the Investigation of P2X7 Receptors.

Sluyter R, Adriouch S, Fuller S, Nicke A, Sophocleous R, Watson D Int J Mol Sci. 2023; 24(9).

PMID: 37175933 PMC: 10179175. DOI: 10.3390/ijms24098225.


The role of the ATP-adenosine axis in ischemic stroke.

Schadlich I, Winzer R, Stabernack J, Tolosa E, Magnus T, Rissiek B Semin Immunopathol. 2023; 45(3):347-365.

PMID: 36917241 PMC: 10279578. DOI: 10.1007/s00281-023-00987-3.